Causaly’s Post

How are pharmacology disease state models used for drug development? In this interview with Pharmacology Manager Meiling Hou, we explore the challenges of developing new models and the approach QPS Holdings, LLC is leveraging to mitigate them >>> https://hubs.ly/Q02wxr700

In light of scientific and technological advancements, the shift in drug development towards novel modalities, and the evolving regulatory landscape, it has been proposed to revisit, adapt, and evolve the ICH-S7A guidance. An ACT Annual Meeting symposium chaired by Derek Leishman and Lorrene Buckley will discuss a concept paper with insights from regulators and experts in in vitro and in vivo safety pharmacology. Topics will include the use of adversity in safety pharmacology, the emphasis on human-based in vitro and in silico test systems, the latest validated technology platforms, principles for model validation and qualification, and the refinement of the above points to ensure the guideline is modality-agnostic and sustainable. The symposium will conclude with a panel discussion featuring Dr. Jufeng Wang and Dr. Todd Bourcier. Register for the Annual Meeting here: https://lnkd.in/ek5UQRza #ACTOX2024

Missed our recent webinar on why modeling and simulation is so important in the drug development industry? Don’t worry, you can catch up now with on-demand! Don’t miss by IQVIA’s Director of Quantitative Clinical Pharmacology Zheng Liu, PhD, as he presents real-world examples that bring these approaches to life. https://bit.ly/4cnfy93 #drugdevelopment #simulation

How are pharmacology disease state models used for drug development? In this interview with Pharmacology Manager Meiling Hou, we explore the challenges of developing new models and the approach QPS Holdings, LLC is leveraging to mitigate them >>> https://hubs.ly/Q02Hpy400

Today is the last day to register for our May 23 webinar "The State-of-the-Art in Secondary Pharmacology and its Impact on the Safety of New Medicines" Register Now➡️https://ow.ly/6Rte50RsZtQ This webinar is based on a recently published article in Nature Reviews in Drug Discovery. Read it here: https://rdcu.be/dIyCf

Nature Reviews Drug Discovery highlights the state of the art in secondary pharmacology and its impact on the safety of new medicines: 💡 A top-level view of the current state of the art in secondary pharmacology screening. 💡 Best practices, including additional safety-associated targets not covered by most current screening panels. 💡 Approaches for interpreting and reporting off-target activities. 💡 Assessment of the safety impact of secondary pharmacology screening. 💡 Perspective on opportunities and challenges in this rapidly developing field. https://hubs.la/Q02ydSmK0 #drugdiscovery #cardiacsafety #ionchannels

Great webinar by the #certara team discussing the dynamic synergy between Quantitative Systems Pharmacology(QSP) and Pharmacometrics(PMX). Learn more on how this powerful combination is reshaping drug development.

I am pleased to share my presentation on "Intracellular Receptors," which I prepared for the Pharmacology course. This presentation covers the structure of intracellular receptors, their mechanism of action, functional characteristics, and therapeutic relevance. created by Mohamed Essam. #Pharmacology #Education #Pharmacy #Research

Traditional drug development methods can't always predict real-world outcomes. Explore the dynamic synergy between Quantitative Systems Pharmacology (QSP) and Pharmacometrics (PMX) in our latest ISoP webinar. Discover how this combo is reshaping drug development with more accurate insights. Watch the full webinar: https://ow.ly/WoJt50Roh5s

Improving the success rate of drug development can be achieved with robust and effective pharmacology disease state models. In this interview, Meiling Hou shares a behind-the-scenes insight into the challenges of developing these models and the steps QPS Holdings, LLC are taking to overcome them >>> https://hubs.ly/Q02wxmlH0